Linio Biotech
Tience® — sterile, cell-free injectable derived from adipose tissue that restarts the skin's own regeneration (scars, ageing-related defects, soft-tissue repair). Positioned as a regenerative platform, not a single product. Tampere University spin-out (research from 2005, company 2017); launched in Finland 2023 and Sweden 2025, clinical studies ongoing.
The row
- Stage
- In market — Product is being sold
- Location
- Helsinki
- Founded
- 2017
- Research origin
- Tampere Univ.
- Business ID
- 2871201-8 · Finnish trade register
- Funding
- ~€9M (2023)
Links
Where this sits on the map
Linio Biotech is one of 33 companies in Therapeutics & Diagnostics. The others:
How this row was decided
Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗